Coronavirus Vaccine ‘Sputnik V’ developed by Russia is expected to arrive Ganesh Shankar Vidyarthi Medical College in Kanpur by next week for the second and third phase of vaccine’s human clinical trials. ALSO READ | Dr Reddy’s Gets DCGI Nod To Conduct Stage 2/3 Human Trials For Russia’s Sputnik V Covid-19 Vaccine
Sputnik V is an adenovirus vector-based vaccine, which was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11. In September 2020, Dr. Reddy’s Lab and RDIF entered into a partnership to conduct clinical trials and distribute the vaccine in the country. As part of the agreement, the RDIF will supply 100 million doses of the Vaccine to the country upon approval.
After approval from the Drug Controller General of India (DCGI), the pharma giant Dr Reddy’s Laboratories is set to test the Russian Sputnik V vaccine against Covid-19 on 100 volunteers in India. Once the testing is complete and the vaccine is approved, the RDIF will be referring 100 million doses of Sputnik V to Dr. Reddy’s lab.
According to a Sputnik news report, Gamaleya National Research Center director Alexander Gintsburghas claimed that vaccine used inanimate particles created on the basis of adenovirus. He considered said that there are no concerns the vaccine could cause any harm to a person’s health.
In Russia around 40,000 subjects are going through phase three clinical trials of the Sputnik V vaccine and the UAE also started the phase 3 clinical trials of the vaccine last week.
Russia has named its first COVID-19 vaccine Sputnik V after its Soviet-era satellite, that was the first one from the globe to get launched into space. Naming it after its satellite, Moscow has tend to showcase its success at becoming the first country to develop the vaccine for Coronavirus which has already killed almost 20 million people across the globe.